Literature DB >> 25927480

Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications.

Manuel de Lera Ruiz1, Richard L Kraus1.   

Abstract

The tremendous therapeutic potential of voltage-gated sodium channels (Na(v)s) has been the subject of many studies in the past and is of intense interest today. Na(v)1.7 channels in particular have received much attention recently because of strong genetic validation of their involvement in nociception. Here we summarize the current status of research in the Na(v) field and present the most relevant recent developments with respect to the molecular structure, general physiology, and pharmacology of distinct Na(v) channel subtypes. We discuss Na(v) channel ligands such as small molecules, toxins isolated from animal venoms, and the recently identified Na(v)1.7-selective antibody. Furthermore, we review eight characterized ligand binding sites on the Na(v) channel α subunit. Finally, we examine possible therapeutic applications of Na(v) ligands and provide an update on current clinical studies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25927480     DOI: 10.1021/jm501981g

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  97 in total

1.  Nav1.7 Inhibitors: Potential Effective Therapy for the Treatment of Chronic Pain.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2015-08-14       Impact factor: 4.345

2.  Deleterious protein-altering mutations in the SCN10A voltage-gated sodium channel gene are associated with prolonged QT.

Authors:  M D Abou Ziki; S B Seidelmann; E Smith; G Atteya; Y Jiang; R G Fernandes; M A Marieb; J G Akar; A Mani
Journal:  Clin Genet       Date:  2017-05-18       Impact factor: 4.438

3.  Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel NaV1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy Volunteers.

Authors:  Michael E Rothenberg; Michael Tagen; Jae H Chang; Janel Boyce-Rustay; Michel Friesenhahn; David H Hackos; Avis Hains; Dan Sutherlin; Michael Ward; William Cho
Journal:  Clin Drug Investig       Date:  2019-09       Impact factor: 2.859

4.  Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement.

Authors:  Isaac E Marx; Thomas A Dineen; Jessica Able; Christiane Bode; Howard Bregman; Margaret Chu-Moyer; Erin F DiMauro; Bingfan Du; Robert S Foti; Robert T Fremeau; Hua Gao; Hakan Gunaydin; Brian E Hall; Liyue Huang; Thomas Kornecook; Charles R Kreiman; Daniel S La; Joseph Ligutti; Min-Hwa Jasmine Lin; Dong Liu; Jeff S McDermott; Bryan D Moyer; Emily A Peterson; Jonathan T Roberts; Paul Rose; Jean Wang; Beth D Youngblood; Violeta Yu; Matthew M Weiss
Journal:  ACS Med Chem Lett       Date:  2016-09-21       Impact factor: 4.345

5.  Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent NaV1.7 inhibitors.

Authors:  Brian A Sparling; S Yi; J Able; H Bregman; Erin F DiMauro; R S Foti; H Gao; A Guzman-Perez; H Huang; M Jarosh; T Kornecook; J Ligutti; B C Milgram; B D Moyer; B Youngblood; V L Yu; M M Weiss
Journal:  Medchemcomm       Date:  2016-12-02       Impact factor: 3.597

6.  The discovery of a potent Nav1.3 inhibitor with good oral pharmacokinetics.

Authors:  D C Pryde; N A Swain; P A Stupple; C W West; B Marron; C J Markworth; D Printzenhoff; Z Lin; P J Cox; R Suzuki; S McMurray; G J Waldron; C E Payne; J S Warmus; M L Chapman
Journal:  Medchemcomm       Date:  2017-04-28       Impact factor: 3.597

7.  Manipulation of a spider peptide toxin alters its affinity for lipid bilayers and potency and selectivity for voltage-gated sodium channel subtype 1.7.

Authors:  Akello J Agwa; Poanna Tran; Alexander Mueller; Hue N T Tran; Jennifer R Deuis; Mathilde R Israel; Kirsten L McMahon; David J Craik; Irina Vetter; Christina I Schroeder
Journal:  J Biol Chem       Date:  2020-03-05       Impact factor: 5.157

8.  Bimodal Imaging of Mouse Peripheral Nerves with Chlorin Tracers.

Authors:  Junior Gonzales; Javier Hernández-Gil; Thomas C Wilson; Dauren Adilbay; Mike Cornejo; Paula Demétrio de Souza Franca; Navjot Guru; Christina I Schroeder; Glenn F King; Jason S Lewis; Thomas Reiner
Journal:  Mol Pharm       Date:  2021-01-06       Impact factor: 4.939

Review 9.  Matrix metalloproteinases - From the cleavage data to the prediction tools and beyond.

Authors:  Piotr Cieplak; Alex Y Strongin
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2017-03-24       Impact factor: 4.739

10.  Matrix Metalloproteinase (MMP) Proteolysis of the Extracellular Loop of Voltage-gated Sodium Channels and Potential Alterations in Pain Signaling.

Authors:  Albert G Remacle; Sonu Kumar; Khatereh Motamedchaboki; Piotr Cieplak; Swathi Hullugundi; Jennifer Dolkas; Veronica I Shubayev; Alex Y Strongin
Journal:  J Biol Chem       Date:  2015-08-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.